Results from a phase III trial reveal that men with advanced prostate cancer can significantly benefit from a new medication, abiraterone acetate, called Zytiga. The researchers found that the drug maintained patients' quality of life, slowed down the spread of cancer, and delayed the development of pain and deterioration of the patients' overall condition. During the trial, individuals assigned to placebo were allowed to switch to zytiga because of the favorable results...
Fonte: healthnews.com
Indique esta NotÃcia
Compartilhar
A PHP Error was encountered
Severity: User Warning
Message: Smarty error: unable to read resource: "indiquemat_healthnews.tpl"
Filename: libs/Smarty.class.php
Line Number: 1095
